biote Corp.
BTMD
NASDAQ·Healthcare·Medical - Care Facilities·Mkt cap $68.1M
$1.55
▼ -0.32%
P/E
10.46
Mkt Cap
$68.1M
52-Wk Range
$1.27–$3.58
52-Week Range
$1.27 - $3.58
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 55.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary sterile pellet insertion technology and methodology
- Established network of Biote-certified practitioners creating switching costs
- Recurring revenue model through ongoing practitioner supplies and patient treatments
- Integrated platform combining diagnosis, treatment, and supplementation
- Strong brand recognition in the hormone optimization and functional medicine space
Bear Case
2 risks
- Above-average volatility (beta 1.6).
- Extreme premium - high expectations embedded
Growth
Stable outlook
Expansion of Biote-certified practitioner network across new geographic markets
Value
Extreme premium - high expectations embedded
Momentum
Falling
-34.0% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying BTMD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of -$0.23 vs $0.03 consensus (-962.4% surprise). Revenue of $44.2M vs $46.1M expected (-4.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-962.4%
Revenue trend · last 8Q
—
+9%
+5%
-1%
-7%
-7%
-8%
-9%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$51.4M
$49.8M
$49.0M
$48.9M
$48.0M
$46.4M
$44.9M
$44.2M
Margins · last 8Q
Gross
65.4%
Operating
-7.9%
Profit
-14.8%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: B. Riley · Aug 10, 2026
vs Industry
How BTMD stacks vs Medical - Care Facilities
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related